Alpha Tau Medical (NASDAQ:DRTS) Issues Earnings Results, Misses Estimates By $0.01 EPS

Key Points

• Missed estimates: Alpha Tau Medical reported Q results of ($0.14) EPS vs. a ($0.13) consensus, missing by $0.01, and shares traded down about 2% on the news.
• Market snapshot: The stock opened at $6.58 with a market cap of $557.7M, a negative P/E of -12.67, and a 52‑week range of $2.30–$8.60.
• Mixed analyst view with a "Hold" consensus: Two Buys, two Holds and one Sell produce a MarketBeat consensus "Hold" and an average target price of $7.00, while Citigroup recently cut its target from $8 to $7.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01), Zacks reports.

Alpha Tau Medical Trading Down 2.0%

Alpha Tau Medical stock opened at $6.58 on Tuesday. The firm has a market capitalization of $557.69 million, a P/E ratio of -12.67 and a beta of 1.02. The stock has a fifty day moving average price of $6.94 and a 200 day moving average price of $5.07. Alpha Tau Medical has a 52 week low of $2.30 and a 52 week high of $8.60.

Hedge Funds Weigh In On Alpha Tau Medical

A number of large investors have recently modified their holdings of DRTS. Envestnet Asset Management Inc. acquired a new stake in shares of Alpha Tau Medical in the third quarter worth $62,000. Bank of America Corp DE lifted its holdings in Alpha Tau Medical by 2,779.1% in the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company's stock worth $101,000 after buying an additional 21,677 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company's stock valued at $116,000 after purchasing an additional 17,500 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Alpha Tau Medical in the 3rd quarter valued at approximately $170,000. Finally, Mariner LLC boosted its stake in Alpha Tau Medical by 185.8% during the 3rd quarter. Mariner LLC now owns 123,250 shares of the company's stock valued at $556,000 after acquiring an additional 80,129 shares during the last quarter. 2.65% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Citigroup reduced their price target on Alpha Tau Medical from $8.00 to $7.00 and set a "buy" rating on the stock in a research report on Wednesday, December 10th. Zacks Research upgraded shares of Alpha Tau Medical from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 17th. HC Wainwright restated a "buy" rating on shares of Alpha Tau Medical in a research report on Wednesday, December 10th. Piper Sandler reiterated a "neutral" rating and set a $5.00 target price on shares of Alpha Tau Medical in a research note on Wednesday, March 4th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Alpha Tau Medical in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $7.00.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company's core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company's lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.